ArticleTaehan Yongsang Uihakhoe chi2022
LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies.
Article in Taehan Yongsang Uihakhoe chi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Network meta-analysis and validation study of expanded liver transplantation criteria for hepatocellular carcinoma: Significant role of alpha-fetoprotein.Clinical and molecular hepatology · 2026Pooled it
- Magnetic resonance imaging findings after stereotactic body radiation therapy for hepatocellular carcinoma - a scoping literature review.Clinical and translational radiation oncology · 2026Review
- LI-RADS TRA V2024: innovations in imaging assessment of hepatocellular carcinoma response to locoregional therapies.Abdominal radiology (New York) · 2026Review
- Association of LR treatment response category with outcome of patients with hepatocellular carcinoma on explant pathology.Abdominal radiology (New York) · 2025Article
- CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.Radiology · 2024Review
- [Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation.Life (Basel, Switzerland) · 2023Review
- Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2023Article
- Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.Journal of magnetic resonance imaging : JMRI · 2023Review
- Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To systematically compare the performance of liver imaging reporting and data system treatment response (LR-TR) with the modified Response Evaluation Criteria in Solid Tumors (mRECIST) for diagnosing viable hepatocellular carcinoma (HCC) treated with locoregional therapy (LRT). Materials and Methods: Original studies of intra-individual comparisons between the diagnostic performance of LR-TR and mRECIST using dynamic contrast-enhanced CT or MRI were searched in MEDLINE and EMBASE, up to August 25, 2021. The reference standard for tumor viability was surgical pathology. The meta-analytic pooled sensitivity and specificity of the viable category using each criterion were calculated using a bivariate random-effects model and compared using bivariate meta-regression. Results: For five eligible studies (430 patients with 631 treated observations), the pooled per-lesion sensitivities and specificities were 58% (95% confidence interval [CI], 45%-70%) and 93% (95% CI, 88%-96%) for the LR-TR viable category and 56% (95% CI, 42%-69%) and 86% (95% CI, 72%-94%) for the mRECIST viable category, respectively. The LR-TR viable category provided significantly higher pooled specificity ( Conclusion: The LR-TR algorithm demonstrated better specificity than mRECIST, without a significant difference in sensitivity for the diagnosis of pathologically viable HCC after LRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.